Form D · Pharmaceuticals
California Compounding Company, Inc.
Los Angeles, CA · CIK 0002134601
Offering snapshot reported May 12, 2026 · SEC filing
- Reported sold
- $4.92M Offering amount: $14.5M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 1, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 12, 2026 | Initial | $4,923,273 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-583709
Source: Form D, filed May 12, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Alex Ferriera | Director, Executive |
| Justin Lyle | Director, Executive |
| Tyler Tarr | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
6600 W. Sunset Blvd Suite 237
Los Angeles, CA, 90028
Los Angeles, CA, 90028